Pharma Focus Asia

Amgen Introduces First and Only IMDELLTRA™ T-Cell Engager Therapy for Small Cell Lung Cancer

Amgen has introduced IMDELLTRA™ (tarlatamab-dlle), the first and only T-cell engager therapy for treating extensive-stage small cell lung cancer (ES-SCLC). 

IMDELLTRA™ is unique as the only DLL3-targeting bispecific T-cell engager therapy that activates the patient's own T cells to attack DLL3-expressing tumour cells. IMDELLTRA™ (tarlatamab-dlle) is specifically indicated for adult patients with ES-SCLC who have experienced disease progression following platinum-based chemotherapy.

It has received accelerated approval based on promising response rates and duration of response (DoR) observed in clinical studies. IMDELLTRA™ provides much-needed hope to patients urgently in need of innovative therapies, this long-awaited effective treatment.

Lung cancer remains a complex and devastating disease, with less than 3 percent of ES-SCLC patients surviving beyond five years. 

After decades of stagnation in the treatment options for small cell lung cancer (SCLC), a breakthrough has emerged in the form of IMDELLTRA™, a targeted bispecific therapy. This innovative treatment marks a pivotal moment for the SCLC community, offering renewed hope and possibilities for those battling this aggressive disease. 

With IMDELLTRA™, patients now have access to a treatment that addresses the specific mechanisms driving SCLC progression, potentially leading to improved outcomes and quality of life. This advancement represents a significant milestone in the fight against SCLC and underscores the power of innovation in transforming cancer care.

magazine-slider-imageMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference